

EA8143 (PROSPER RCC) Clinical Trial Results Summary

Testing the Addition of the Drug Nivolumab Before and After Surgery for Renal Cell Cancer

What did this trial involve and who was it for?

The EA8143/PROSPER RCC trial was for patients with kidney cancer (also called renal cell cancer [RCC]), whose cancer was at high risk of returning (recurring) and who were about to undergo full or partial removal of the kidney. The trial was testing if patients would have better results with the addition of the immunotherapy drug nivolumab before and after surgery compared to the usual treatment of surgery alone. A total of 785 patients participated in EA8143/PROSPER RCC.

What are the results?

At a preliminary analysis, results showed that there was no difference in how long patients lived before their cancer returned between the two groups (surgery plus nivolumab or surgery alone). The trial was stopped early because of this.

What do the results mean for patients?

The standard treatment for RCC remains surgery alone with careful monitoring. Additionally, a trial that was conducted at the same time as EA8143/PROSPER RCC showed that a year of a different immunotherapy drug, pembrolizumab, following surgery could lower the risk of recurrence in some patients with stage II or III clear cell kidney cancer. Current ongoing trials are further examining the usefulness of certain biomarkers to help guide the treatment of this disease.

For more information, go to:

- United States National Institutes of Health (NIH) Library of Medicine:
<https://clinicaltrials.gov/ct2/show/NCT03055013>
 - *Annals of Oncology*:
[https://www.annalsofoncology.org/article/S0923-7534\(22\)03950-3/fulltext](https://www.annalsofoncology.org/article/S0923-7534(22)03950-3/fulltext)
 - ECOG-ACRIN Website:
<https://ecog-acrin.org/press-release-ecog-acrin-completes-the-first-randomized-phase-3-clinical-trial-of-neoadjuvant-immunotherapy-in-patients-with-kidney-cancer/>
-

About ECOG-ACRIN

This trial was led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). ECOG-ACRIN is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN is a component of the National Cancer Institute's National Clinical Trials Network. Learn more at www.ecog-acrin.org.

To all the patients that participated in this trial, thank you. Without the involvement of patients like you, this research would not have been completed.